MARKET

BDTX

BDTX

BLACK DIAMOND THERAPEUTICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.86
-0.87
-2.58%
Opening 10:59 07/13 EDT
OPEN
34.08
PREV CLOSE
33.73
HIGH
35.03
LOW
32.65
VOLUME
18.93K
TURNOVER
--
52 WEEK HIGH
46.25
52 WEEK LOW
17.63
MARKET CAP
1.18B
P/E (TTM)
-22.2704
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BDTX stock price target is 51.33 with a high estimate of 53.00 and a low estimate of 50.00.

EPS

BDTX News

More
Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
GlobeNewswire · 06/16 12:45
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 06/04 12:13
Black Diamond Therapeutics to Present at the Jefferies Virtual Healthcare Conference
GlobeNewswire · 05/27 12:45
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18)
Benzinga · 05/19 12:27
Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020
GlobeNewswire · 05/13 22:15
Black Diamond Therapeutics Highlights Accepted Abstract For BDTX-189 At ASCO May 29-31
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the design of MasterKey-01,
Benzinga · 05/13 21:49
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 05/13 11:40
Black Diamond Therapeutics EPS misses by $0.04
Black Diamond Therapeutics (NASDAQ:BDTX): Q1 GAAP EPS of -$0.51 misses by $0.04. Cash and equivalents of $357.19M (+130.9% Q/Q) Press Release
seekingalpha · 05/12 17:01

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+1.49%

Hot Stocks

Symbol
Price
%Change

About BDTX

Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. The Company has designed its lead product candidate, BDTX-189, to block the function of an undrugged family of oncogenic proteins defined by mutations which occur across a range of tumor types, and which affect both the epidermal growth factor receptor (EGFR) and the tyrosine-protein kinase ErbB-2, or HER2.
More

Webull offers kinds of Black Diamond Therapeutics Inc stock information, including NASDAQ:BDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDTX stock methods without spending real money on the virtual paper trading platform.